Herceptin (trastuzumab)

Neoadjuvant therapy with dual human epidermal growth factor receptor 2 (HER2) blockade using trastuzumab and pertuzumab combined with chemotherapy is the standard of care for patients with locally advanced HER2-positive breast cancer...HR status is a strong and independent predictor of pCR in HER2-positive breast cancer patients receiving neoadjuvant dual blockade. Patients with HR- disease derive the most benefit from this regimen, highlighting the need for tailored therapeutic strategies to improve outcomes for the HR+ subgroup.

P1/2, N=24, Active, not recruiting, Institut fuer Klinische Krebsforschung IKF GmbH | Recruiting --> Active, not recruiting

The 4AC-4THP regimen-comprising doxorubicin and cyclophosphamide followed by docetaxel, trastuzumab, and pertuzumab-has been widely adopted as neoadjuvant treatment for HER2-positive breast cancer. Subclinical cardiac dysfunction was common but mild and manageable. These findings provide further support for its use in neoadjuvant settings with appropriate monitoring strategies, especially in real-world clinical settings with variable access to monitoring resources.

Recombinant HSP70, in conjugation with the monoclonal antibodies trastuzumab and bevacizumab, was employed for both in vivo and in vitro treatment of tumor cells. Histopathological analysis, along with the observed therapeutic efficacy, confirmed the safety of this approach. Overall, stimulating the immune system against cancer cells by targeting innate immune responses could enhance the effectiveness of targeted therapies.

Both ALBI score and age are independent predictors influencing trastuzumab resistance in HER-2 positive BC patients. Their combined use enhances predictive accuracy and may facilitate early identification of patients at increased risk of developing resistance to trastuzumab.

Both trastuzumab and doxorubicin are currently in clinical use, but with safety issues involving each of them. The new ADC has the potential to increase the proapoptotic markers such as Bax, cleaved caspase 9, and Cytc at 5 and 10 μg/mL against the human breast tumor cell line BT474.

Although pCR was not associated with a lower overall risk of CNS recurrence, it predicted a reduced risk in HER2-positive disease. Isolated CNS relapse predominated, suggesting a sanctuary effect.

P1, N=27, Recruiting, Institut Paoli-Calmettes | Trial completion date: Feb 2026 --> Mar 2027 | Trial primary completion date: Mar 2025 --> Mar 2027

A 62-year-old woman with HER2-positive, cT4bN2M0 breast cancer receiving neoadjuvant trastuzumab, carboplatin, and docetaxel presented with fever, headache, profound fatigue, pallor, and retinal hemorrhages...The patient was managed with blood component transfusions, filgrastim, and empirical piperacillin-tazobactam...Gram-negative infections caused by phytobacteria are likely underreported with the automated VITEK-2 identification system. This first molecularly confirmed case of Phytobacter diazotrophicus identified by 16S rDNA sequencing in India underscores the need for heightened clinical awareness, prompt and accurate microbiological identification, and vigilance regarding antimicrobial resistance, especially in the immunocompromised population.

These data support systemic therapy as an approach in HER2+ breast cancer LM. ClinicalTrials.gov registration: NCT03501979 .

P1/2, N=80, Recruiting, ALX Oncology Inc. | Not yet recruiting --> Recruiting

Patients with microinvasive or small HER2+ node-negative breast cancer experience favorable outcomes. The pT1b group had higher histological grades and proliferative indices. Patients with pT1b disease or higher tumor grades were more likely to receive trastuzumab. While trastuzumab is recommended for pT1b disease with strong evidence, its use in pT1a disease should be balanced against its unclear benefits and known toxicities.